Industry

FTSE plummets as markets rocked by Moderna chief's Covid warning


Senior Investment and Markets Analyst at Hargreaves Lansdown, Susannah Streeter said: “Amid the pessimism about the effectiveness of vaccines, AstraZeneca is among the biggest fallers on the FTSE 100 so far.

“Its vaccine has been produced at cost and now investors are clearly wondering if they will ever see a profit from this part of the business.”

Pfizer and its partner BioNTech however have struck a more positive tone saying last week they could produce and ship an updated version of their vaccine within 100 days to tackle any immunity evasion from Omicron.

Pfizer saw a boost to its share price at the end of trading on Friday whilst BioNTech is currently up 4.17 percent.





READ SOURCE

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.